Clinical and virologic features of monoclonal B-cell PTLDs
Case . | Histology . | Sex . | TX . | Age at TX, y . | Immune suppression . | Interval from TX, mo . | Tumor site . | Stage . | EBV . | Treatment modalities* . | Response . | Outcome, mo from PTLD . |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2614 | P-PTLD | M | Lung | 46 | C + A | 5 | Lung | IIE | + | CT | SD | Death at 1 mo |
2618 | P-PTLD | M | Heart | 67 | C + A | 6 | Lung | IIE | + | No treatment | CR | Alive at 76 mo |
2913A | P-PTLD | M | Heart | 38 | C + A | 152 | Tonsil | IE | - | CT + RT | CR | Death at 16 mo |
2916 | P-PTLD | M | Heart | 54 | C + A | 6 | Lung | IE | + | S | CR | Alive at 54 mo |
3462 | P-PTLD | M | Liver | 61 | C + A | 7 | Liver | IE | + | NA | NA | Autoptic diagnosis |
3464 | P-PTLD | M | Liver | 59 | C + A | 5 | Liver | IE | + | S + anti-CD20 + HDIg | CR | Alive at 27 mo |
3468 | P-PTLD | M | Heart | 53 | C + A | 2 | Tongue | IE | + | No treatment | CR | Alive at 23 mo |
3471 | P-PTLD | M | Liver | 33 | C + A | 7 | Liver | IV | + | CT + HDIg + RF | CR | Alive at 31 mo |
3515 | P-PTLD | M | Heart | 13 | C + A | 79 | Lymph node | II | - | CT | PD | Death at 18 mo |
3516 | P-PTLD | M | Heart | 18 | C + A | 22 | Lymph node | II | + | CT | NE | Death at 20 mo |
3519 | P-PTLD | M | Heart | 59 | C + A | 84 | Lymph node | III | - | CT | NE | Death at 6 mo |
3521 | P-PTLD | F | Heart | 14 | C + A | 51 | Lymph node | I | + | S | CR | Alive at 41 mo |
2798 | DLBCL, CB | F | Kidney | 58 | C + A | 103 | Lymph node | II | - | CT + HDIg | CR | Alive at 45 mo |
2898 | DLBCL, CB | M | Heart | 34 | C + A | 81 | Lymph node | III | - | CT + S + HDIg | CR | Alive at 52 mo |
2909 | DLBCL, CB | M | Heart | 59 | C + A | 44 | Spleen | III | - | No treatment | PD | Death at 5 mo |
2912 | DLBCL, CB | M | Heart | 43 | C + A | 113 | Mesenteric mass | II | - | CT | PR | Death at 15 mo |
2914 | DLBCL, CB | M | Heart | 48 | C + A | 110 | Stomach | IV | - | CT | CR | Alive at 70 mo |
3459 | DLBCL, CB | M | Lung | 27 | C + A | 128 | Lymph node | IV | + | CT + anti-CD20 + HDIg | CR | Alive at 25 mo |
3465 | DLBCL, CB | F | Liver | 55 | C + A | 95 | Lymph node | III | - | CT | CR | Alive at 21 mo |
3466 | DLBCL, CB | M | Liver | 45 | C + A | 104 | Skin | IE | - | CT + S | CR | Alive at 22 mo |
3467 | DLBCL, CB | M | Heart | 52 | C + A | 128 | Lymph node | IV | + | P | NA | Death at 1 d |
3518 | DLBCL, CB | M | Heart | 55 | C + A | 60 | Lymph node | II | + | CT + RT | PD | Death at 8 mo |
3522 | DLBCL, CB | M | Liver | 1 | FK506 | 29 | Jejunum | IIE | - | CT + S + anti-CD20 | CR | Alive at 41 mo |
3523 | DLBCL, CB | F | Heart | 12 | C + A | 102 | Lymph node | I | - | RT + anti-CD20 | CR | Alive at 29 mo |
3524 | DLBCL, CB | M | Heart | 21 | C + A | 78 | Skin | IV | - | CT | CR | Death at 12 mo |
3527 | DLBCL, CB | M | Kidney | 28 | C + A | 51 | Lymph node | III | - | CT | NE | Death at 3 mo |
3528 | DLBCL, CB | M | Heart | 16 | C + A | 95 | Lymph node | II | - | CT + anti-CD20 | PR | Death at 4 mo |
3530 | DLBCL, CB | M | Heart | 58 | C + A | 144 | Lymph node | II | - | RT + anti-CD20 | CR | Alive at 15 mo |
2616 | DLBCL, IB | F | Liver | 39 | C + A | 63 | Peritoneum | IV | + | CT + HDIg | CR | Alive at 60 mo |
2620 | DLBCL, IB | M | Kidney | 64 | C + A | 36 | Liver | IV | + | NA | NA | Autoptic diagnosis |
2621 | DLBCL, IB | M | Heart | 56 | C + A | 5 | Lung | IV | + | NA | NA | Autoptic diagnosis |
2799 | DLBCL, IB | M | Heart | 56 | C + A | 43 | Skin | IV | + | CT + HDIg | SD | Death at 4 months |
2802 | DLBCL, IB | M | Heart | 45 | C + A | 28 | Mediastinum | IV | + | CT + HDIg | PR | Death at 3 mo |
2803 | DLBCL, IB | F | Kidney | 49 | C + A | 64 | Stomach | IIE | - | CT + S | CR | Death at 16 mo |
2892 | DLBCL, IB | M | Heart | 44 | FK506 + A | 42 | Retroperitoneum | I | + | IFN + HDIg | CR | Alive at 137 mo |
2895 | DLBCL, IB | M | Kidney | 46 | C + A | 72 | Lymph node | III | + | NA | NA | Autoptic diagnosis |
2911 | DLBCL, IB | M | Heart | 42 | C + A | 90 | Heart | IE | + | CT | PR | Death at 3 mo |
2915 | DLBCL, IB | M | Heart | 56 | C + A | 56 | Lymph node | II | + | CT | PR | Death at 1 mo |
3461 | DLBCL, IB | M | Kidney | 30 | na | 72 | Tonsil | IIE | + | NK | NK | NK |
3469 | DLBCL, IB | F | Kidney | 26 | na | 90 | Jejunum | IIE | - | NK | NK | NK |
CT + S + RT + HDIg + | ||||||||||||
3476 | DLBCL, IB | M | Heart | 53 | C + A | 108 | Skin | IE | + | CTL | CR | Death at 38 mo |
3517 | DLBCL, IB | M | Heart | 49 | C + A | 84 | Lymph node | IV | - | NA | NA | Autoptic diagnosis |
3520 | DLBCL, IB | M | Kidney | 15 | C + P | 156 | Kidney | IE | + | CT + S + RT | PD | Death at 4 mo |
3525 | DLBCL, IB | F | Kidney | 21 | C + A | 108 | Spleen | IV | - | CT | NE | Death at 1 mo |
3529 | DLBCL, IB | F | Heart | 6 | C + A | 72 | Lymph node | III | + | CT + anti-CD20 | CR | Alive at 21 mo |
2861 | DLBCL, AP | M | Kidney | 47 | C + A | 77 | Lymph node | III | - | CT | PD | Death at 6 mo |
2913B | DLBCL, AP | M | Heart | 38 | C + A | 158 | Tonsil | IE | + | CT + RT | PD | Death at 10 mo |
3458 | DLBCL, AP | F | Kidney | 60 | C + A | 14 | Skin | IV | + | CT + anti-CD20 + HDIg | PR | Death at 6 mo |
2617 | BL/BLL | M | Heart | 51 | C + A | 38 | Lung | IV | + | NK | PD | Death at 10 d |
2890 | BL/BLL | M | Heart | 27 | C + A | 106 | Tonsil | IE | - | CT + RT | PD | Death at 22 mo |
3463 | BL/BLL | M | Heart | 50 | C + A | 92 | Skin | IV | + | CT + HDIg | CR | Alive at 57 mo |
3526 | BL/BLL | M | Heart | 5 | C + A | 94 | Jaw | IE | + | CT + RT | PR | Death at 18 mo |
Case . | Histology . | Sex . | TX . | Age at TX, y . | Immune suppression . | Interval from TX, mo . | Tumor site . | Stage . | EBV . | Treatment modalities* . | Response . | Outcome, mo from PTLD . |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2614 | P-PTLD | M | Lung | 46 | C + A | 5 | Lung | IIE | + | CT | SD | Death at 1 mo |
2618 | P-PTLD | M | Heart | 67 | C + A | 6 | Lung | IIE | + | No treatment | CR | Alive at 76 mo |
2913A | P-PTLD | M | Heart | 38 | C + A | 152 | Tonsil | IE | - | CT + RT | CR | Death at 16 mo |
2916 | P-PTLD | M | Heart | 54 | C + A | 6 | Lung | IE | + | S | CR | Alive at 54 mo |
3462 | P-PTLD | M | Liver | 61 | C + A | 7 | Liver | IE | + | NA | NA | Autoptic diagnosis |
3464 | P-PTLD | M | Liver | 59 | C + A | 5 | Liver | IE | + | S + anti-CD20 + HDIg | CR | Alive at 27 mo |
3468 | P-PTLD | M | Heart | 53 | C + A | 2 | Tongue | IE | + | No treatment | CR | Alive at 23 mo |
3471 | P-PTLD | M | Liver | 33 | C + A | 7 | Liver | IV | + | CT + HDIg + RF | CR | Alive at 31 mo |
3515 | P-PTLD | M | Heart | 13 | C + A | 79 | Lymph node | II | - | CT | PD | Death at 18 mo |
3516 | P-PTLD | M | Heart | 18 | C + A | 22 | Lymph node | II | + | CT | NE | Death at 20 mo |
3519 | P-PTLD | M | Heart | 59 | C + A | 84 | Lymph node | III | - | CT | NE | Death at 6 mo |
3521 | P-PTLD | F | Heart | 14 | C + A | 51 | Lymph node | I | + | S | CR | Alive at 41 mo |
2798 | DLBCL, CB | F | Kidney | 58 | C + A | 103 | Lymph node | II | - | CT + HDIg | CR | Alive at 45 mo |
2898 | DLBCL, CB | M | Heart | 34 | C + A | 81 | Lymph node | III | - | CT + S + HDIg | CR | Alive at 52 mo |
2909 | DLBCL, CB | M | Heart | 59 | C + A | 44 | Spleen | III | - | No treatment | PD | Death at 5 mo |
2912 | DLBCL, CB | M | Heart | 43 | C + A | 113 | Mesenteric mass | II | - | CT | PR | Death at 15 mo |
2914 | DLBCL, CB | M | Heart | 48 | C + A | 110 | Stomach | IV | - | CT | CR | Alive at 70 mo |
3459 | DLBCL, CB | M | Lung | 27 | C + A | 128 | Lymph node | IV | + | CT + anti-CD20 + HDIg | CR | Alive at 25 mo |
3465 | DLBCL, CB | F | Liver | 55 | C + A | 95 | Lymph node | III | - | CT | CR | Alive at 21 mo |
3466 | DLBCL, CB | M | Liver | 45 | C + A | 104 | Skin | IE | - | CT + S | CR | Alive at 22 mo |
3467 | DLBCL, CB | M | Heart | 52 | C + A | 128 | Lymph node | IV | + | P | NA | Death at 1 d |
3518 | DLBCL, CB | M | Heart | 55 | C + A | 60 | Lymph node | II | + | CT + RT | PD | Death at 8 mo |
3522 | DLBCL, CB | M | Liver | 1 | FK506 | 29 | Jejunum | IIE | - | CT + S + anti-CD20 | CR | Alive at 41 mo |
3523 | DLBCL, CB | F | Heart | 12 | C + A | 102 | Lymph node | I | - | RT + anti-CD20 | CR | Alive at 29 mo |
3524 | DLBCL, CB | M | Heart | 21 | C + A | 78 | Skin | IV | - | CT | CR | Death at 12 mo |
3527 | DLBCL, CB | M | Kidney | 28 | C + A | 51 | Lymph node | III | - | CT | NE | Death at 3 mo |
3528 | DLBCL, CB | M | Heart | 16 | C + A | 95 | Lymph node | II | - | CT + anti-CD20 | PR | Death at 4 mo |
3530 | DLBCL, CB | M | Heart | 58 | C + A | 144 | Lymph node | II | - | RT + anti-CD20 | CR | Alive at 15 mo |
2616 | DLBCL, IB | F | Liver | 39 | C + A | 63 | Peritoneum | IV | + | CT + HDIg | CR | Alive at 60 mo |
2620 | DLBCL, IB | M | Kidney | 64 | C + A | 36 | Liver | IV | + | NA | NA | Autoptic diagnosis |
2621 | DLBCL, IB | M | Heart | 56 | C + A | 5 | Lung | IV | + | NA | NA | Autoptic diagnosis |
2799 | DLBCL, IB | M | Heart | 56 | C + A | 43 | Skin | IV | + | CT + HDIg | SD | Death at 4 months |
2802 | DLBCL, IB | M | Heart | 45 | C + A | 28 | Mediastinum | IV | + | CT + HDIg | PR | Death at 3 mo |
2803 | DLBCL, IB | F | Kidney | 49 | C + A | 64 | Stomach | IIE | - | CT + S | CR | Death at 16 mo |
2892 | DLBCL, IB | M | Heart | 44 | FK506 + A | 42 | Retroperitoneum | I | + | IFN + HDIg | CR | Alive at 137 mo |
2895 | DLBCL, IB | M | Kidney | 46 | C + A | 72 | Lymph node | III | + | NA | NA | Autoptic diagnosis |
2911 | DLBCL, IB | M | Heart | 42 | C + A | 90 | Heart | IE | + | CT | PR | Death at 3 mo |
2915 | DLBCL, IB | M | Heart | 56 | C + A | 56 | Lymph node | II | + | CT | PR | Death at 1 mo |
3461 | DLBCL, IB | M | Kidney | 30 | na | 72 | Tonsil | IIE | + | NK | NK | NK |
3469 | DLBCL, IB | F | Kidney | 26 | na | 90 | Jejunum | IIE | - | NK | NK | NK |
CT + S + RT + HDIg + | ||||||||||||
3476 | DLBCL, IB | M | Heart | 53 | C + A | 108 | Skin | IE | + | CTL | CR | Death at 38 mo |
3517 | DLBCL, IB | M | Heart | 49 | C + A | 84 | Lymph node | IV | - | NA | NA | Autoptic diagnosis |
3520 | DLBCL, IB | M | Kidney | 15 | C + P | 156 | Kidney | IE | + | CT + S + RT | PD | Death at 4 mo |
3525 | DLBCL, IB | F | Kidney | 21 | C + A | 108 | Spleen | IV | - | CT | NE | Death at 1 mo |
3529 | DLBCL, IB | F | Heart | 6 | C + A | 72 | Lymph node | III | + | CT + anti-CD20 | CR | Alive at 21 mo |
2861 | DLBCL, AP | M | Kidney | 47 | C + A | 77 | Lymph node | III | - | CT | PD | Death at 6 mo |
2913B | DLBCL, AP | M | Heart | 38 | C + A | 158 | Tonsil | IE | + | CT + RT | PD | Death at 10 mo |
3458 | DLBCL, AP | F | Kidney | 60 | C + A | 14 | Skin | IV | + | CT + anti-CD20 + HDIg | PR | Death at 6 mo |
2617 | BL/BLL | M | Heart | 51 | C + A | 38 | Lung | IV | + | NK | PD | Death at 10 d |
2890 | BL/BLL | M | Heart | 27 | C + A | 106 | Tonsil | IE | - | CT + RT | PD | Death at 22 mo |
3463 | BL/BLL | M | Heart | 50 | C + A | 92 | Skin | IV | + | CT + HDIg | CR | Alive at 57 mo |
3526 | BL/BLL | M | Heart | 5 | C + A | 94 | Jaw | IE | + | CT + RT | PR | Death at 18 mo |
TX indicates transplantation; P-PTLD, polymorphic PTLD; M, male; C, cyclosporine A; A, azathioprine; CT, chemotherapy (the regimen varied and was tailored to the patient's age, stage, and performance status); SD, stable disease; CR, complete remission; RT, radiotherapy; S, surgery; NA, not applicable; anti-CD20, rituximab; HDIg, high-dose immunoglobulin; RF, radiofrequency; PD, progressive disease; P, prednisone; NE, not evaluable; F, female; DLBCL, diffuse large B-cell lymphoma; CB, centroblastic; PR, partial remission; P, prednisone; FK506, tacrolimus; IB, immunoblastic; IFN, interferon; na, not available; NK, not known; CTL, cytotoxic T lymphocytes; AP, anaplastic; and BL/BLL, Burkitt lymphoma/Burkitt-like lymphoma.
All patients underwent reduction of immunosuppression, with the exception of cases 3528 and 3529 and cases in whom the diagnosis of PTLD was autoptic.